Analysis of the Consumption of Non-Oncological Medicines: A Methodological Study on Patients of the Ada Cohort.

adolescents and young adults cancer patients defined daily dose fragility medicine consumption pain

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
30 Aug 2021
Historique:
received: 28 06 2021
revised: 18 08 2021
accepted: 25 08 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Cancer patients are identified as fragile patients who are often immunodepressed and subject to secondary diseases. The Ada cohort comprises cancer survivors aged 15-39 years at diagnosis included in 34 Italian cancer registries. This study aimed to analyze the possible excess of non-cancer medicines use on the basis of the medicine database of the Ada cohort. Records of medicines present in the pharmaceutical flows collected by eight Lombardy cancer registries and used by patients with any type of cancer were extracted for the year 2012. Medicine consumption data were processed to assign a defined daily dose value and to evaluate the consumption of medicines belonging to different groups of the ATC (Anatomical Therapeutic Chemical) classification. The values were compared with values in the Lombardy population. Medicine consumption related to 8150 patients was analyzed, for a total of 632,675 records. ATC groups A and C for females and group N for both sexes showed significant increases. Group J for males and group M for females showed intermediate increases, and group H for both sexes showed smaller increases. This method allowed the identification of excess medicine use to reduce cancer therapy side effects and primary disease sequelae in this group of patients.

Identifiants

pubmed: 34574895
pii: healthcare9091121
doi: 10.3390/healthcare9091121
pmc: PMC8468722
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Clin Oncol. 2013 May 1;31(13):1683-9
pubmed: 23530105
J Adolesc Young Adult Oncol. 2020 Oct;9(5):586-593
pubmed: 32283044
Cancer. 2005 Apr 1;103(7):1457-67
pubmed: 15712273
Cancer. 2011 May 15;117(10 Suppl):2289-94
pubmed: 21523748
Semin Oncol. 2010 Jun;37(3):282-96
pubmed: 20709210
J Pediatr Hematol Oncol. 2015 Apr;37(3):161-9
pubmed: 25757020
Cancer. 2019 Jun 15;125(12):2107-2114
pubmed: 30892701
Pharmacoepidemiol Drug Saf. 2021 Aug;30(8):1057-1065
pubmed: 33675260
Crit Rev Oncol Hematol. 2018 Mar;123:57-73
pubmed: 29482780
Cancer. 2014 Aug 1;120(15):2272-81
pubmed: 24888503
CA Cancer J Clin. 2017 Sep;67(5):362-377
pubmed: 28731537
Osteoporos Int. 2014 Dec;25(12):2825-32
pubmed: 25103215
J Nutr Sci. 2020 Oct 08;9:e46
pubmed: 33101663

Auteurs

Giulio Barigelletti (G)

Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Giovanna Tagliabue (G)

Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Sabrina Fabiano (S)

Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Annalisa Trama (A)

Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Alice Bernasconi (A)

Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Claudio Tresoldi (C)

Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Viviana Perotti (V)

Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Andrea Tittarelli (A)

Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Classifications MeSH